Switch theme
Sign up to access all valuation multiples
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
2009
26
Last FY Revenue $0.9M
Last FY EBITDA -$8.0M
$6.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Biovica Intl achieved revenue of $0.9M and an EBITDA of -$8.0M.
Biovica Intl expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biovica Intl valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 94% | XXX | XXX | XXX |
| EBITDA | XXX | -$8.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -892% | XXX | XXX | XXX |
| EBIT | XXX | -$9.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1023% | XXX | XXX | XXX |
| Net Profit | XXX | -$9.2M | XXX | XXX | XXX |
| Net Margin | XXX | -1017% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 14, 2025, Biovica Intl's stock price is SEK 1 (or $0).
Biovica Intl has current market cap of SEK 77.1M (or $8.1M), and EV of SEK 57.3M (or $6.0M).
See Biovica Intl trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.0M | $8.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 14, 2025, Biovica Intl has market cap of $8.1M and EV of $6.0M.
Biovica Intl's trades at 6.6x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Biovica Intl's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biovica Intl's P/E ratio is not available.
See valuation multiples for Biovica Intl and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.1M | XXX | $8.1M | XXX | XXX | XXX |
| EV (current) | $6.0M | XXX | $6.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiovica Intl's revenue per employee in the last FY averaged $35K, while opex per employee averaged $0.4M for the same period.
Biovica Intl's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biovica Intl's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biovica Intl and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -892% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1116% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biovica Intl acquired XXX companies to date.
Last acquisition by Biovica Intl was XXXXXXXX, XXXXX XXXXX XXXXXX . Biovica Intl acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biovica Intl founded? | Biovica Intl was founded in 2009. |
| Where is Biovica Intl headquartered? | Biovica Intl is headquartered in Sweden. |
| How many employees does Biovica Intl have? | As of today, Biovica Intl has 26 employees. |
| Who is the CEO of Biovica Intl? | Biovica Intl's CEO is Mr. Anders Rylander. |
| Is Biovica Intl publicy listed? | Yes, Biovica Intl is a public company listed on STO. |
| What is the stock symbol of Biovica Intl? | Biovica Intl trades under BIOVIC B ticker. |
| When did Biovica Intl go public? | Biovica Intl went public in 2017. |
| Who are competitors of Biovica Intl? | Similar companies to Biovica Intl include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biovica Intl? | Biovica Intl's current market cap is $8.1M |
| Is Biovica Intl profitable? | Yes, Biovica Intl is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
